Introduction {#s1}
============

Asthma is a common respiratory disease affecting approximately 360 million people worldwide and an estimated 3.5--10.3% of the population in France \[[@C1], [@C2]\]. A small proportion of patients with asthma suffer from severe asthma \[[@C3]\], which consists of several clinically distinct phenotypes and endotypes \[[@C4]--[@C7]\]. The severe eosinophilic phenotype is characterised by persistent eosinophilic inflammation, reduced lung function and asthma control, and recurrent exacerbations despite the use of high-dose inhaled corticosteroids (ICS), other controllers and chronic or repeated use of systemic corticosteroids \[[@C4], [@C8]\].

Mepolizumab, an anti-interleukin-5 monoclonal antibody, selectively inhibits eosinophilic inflammation \[[@C9]\] and is approved as an add-on treatment for patients with severe eosinophilic asthma \[[@C10]--[@C12]\]. Randomised controlled trials (RCTs) have shown that, compared with placebo, mepolizumab reduces the rate of exacerbations, decreases oral corticosteroid (OCS) dependence, and improves lung function, asthma control and health-related quality of life \[[@C13]--[@C16]\]. Although data from RCTs can confer critical insights into the clinical efficacy and safety of a therapy, these studies are often designed to meet one specific primary objective, such as assessing changes in OCS dose or exacerbation rate. Moreover, RCTs can include a limited patient population, which is not reflective of the general asthma population, due to narrow eligibility criteria \[[@C17]\]. It is therefore also important to obtain data on the effects of a treatment outside the constraints of a formal clinical trial.

Mepolizumab was approved for use in patients with severe eosinophilic asthma in the European Union in December 2015 \[[@C10]\]. Patients in France were given access to mepolizumab before it became commercially available in February 2018, as part of an early access programme (nominative *autorisation temporaire d\'utilisation* \[temporary use authorisation\] (nATU)), and were later reimbursed by *Sécurité Sociale* \[[@C18]\]. The nATU was restricted to patients deemed unable to wait for commercialisation due to disease severity. A protocol was established between the *Agence Nationale de Sécurité du Médicament et des Produits de Santé* (ANSM) and the manufacturer (GlaxoSmithKline), which mandated the patient monitoring procedure, collection of data relating to efficacy and safety and actual conditions of use. To understand the typical patient pathway and describe the characteristics of patients who received early mepolizumab treatment in a real-world setting, data collected during the nATU plus data retrospectively collected from patient medical records were analysed. The aim was to characterise patients included in the nATU and describe disease severity evolution and treatment modifications up to 24 months after treatment initiation.

Methods {#s2}
=======

Study design and treatment {#s2a}
--------------------------

This retrospective, observational study (GSK ID: 207943; HO-17-18317) included data from hospital medical records of patients with severe eosinophilic asthma who started mepolizumab treatment (100 mg subcutaneously 4-weekly) in France as part of the nATU. Medical data mandated by the nATU protocol were collected from June 9, 2015, to March 2, 2016 (during the nATU), and from March 2, 2016, to February, 2018 (post-nATU), which allowed for a retrospective follow-up period of up to 24 months following treatment initiation. Data recorded during and after the nATU but not mandated by the nATU protocol were also included. This study was declared to the Expert Committee for Research, Studies and Evaluations in Health on December 21, 2017, and the declaration of compliance with reference methodology MR003 was made to the National Commission for Data Protection and Liberties on January 8, 2018.

Participating medical centres {#s2b}
-----------------------------

Participating medical centres had ≥3 patients in the nATU and agreed to their participation. The majority of pulmonology departments involved in this study were based at university hospitals (further details in [supplementary section 1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02345-2019.figures-only#fig-data-supplementary-materials)).

Patients {#s2c}
--------

Patients enrolled in the nATU received ≥1 injection of mepolizumab at a participating centre, evidenced by physician-completed treatment access forms. All delays of 4±1 weeks between two consecutive mepolizumab injections were to be reported. To justify the request for mepolizumab and help inform subsequent validation by the ANSM and GlaxoSmithKline, physicians were required to certify that: the patient had severe eosinophilic asthma (without features of eosinophilic granulomatosis with polyangiitis); no other suitable treatment options were currently available; inclusion in a RCT wasn\'t possible; and the patient\'s clinical health status required an urgent change of treatment to avoid severe exacerbations and/or severe steroid side effects. Treatment access forms included information on blood eosinophil counts, exacerbation rates, symptom control and OCS dose. No strict eligibility criteria were described to allow the request validation by GlaxoSmithKline, and patients had to be willing to disclose their personal medical records.

Endpoints and assessments {#s2d}
-------------------------

The primary objective was to describe the profile of patients included in the nATU, using additional data to those collected within the nATU. Baseline characteristics were assessed over the 12 months preceding mepolizumab initiation, and included: asthma duration; smoking history; geographic localisation; comorbidities; employment status; asthma-induced disability; socio-economic status; complementary health insurance status; number of asthma-related exacerbations, including those requiring hospitalisation or an emergency department (ED) visit; atopic status; blood immunoglobulin (Ig)E, eosinophil and neutrophil levels; OCS dose; previous treatment adherence (estimated by investigators); forced expiratory volume in 1 s (FEV~1~); and FEV~1~/forced vital capacity (FVC) ratio. Asthma exacerbations were defined as disease worsening requiring an emergency department visit, hospitalisation and/or use of OCS for ≥48 h or an increase of ≥50% in daily OCS dose. Atopic status was determined by ≥1 positive skin prick test or allergen-specific IgE blood test (IgE level \>0.1 UI).

Secondary objectives were to describe the evolution of disease control and treatment modifications during the follow-up period (≤24 months after mepolizumab initiation). To assess these, we examined: the number of exacerbations and how they were managed (*e.g.* whether OCS, an mergency department visit and/or hospitalisation were required); FEV~1~; FEV~1~/FVC ratio; and mepolizumab withdrawal date and reason (if applicable). Asthma exacerbation rates and OCS use/dose were also analysed by blood eosinophil count at inclusion (\<300, 300--\<500, 500--\<700 and ≥700 cells·µL^−1^) and an analysis to evaluate the different levels of patients\' responses to mepolizumab over the first 12 months of treatment (based on a ≥50% reduction in exacerbation rate and a ≥50% reduction in OCS dose) was also performed (supplementary sections 2 and 3). Safety endpoints included incidence of adverse events, serious adverse events (SAEs) and adverse events of interest.

Statistical analyses {#s2e}
--------------------

Mean asthma exacerbation rates were reported as exacerbations per patient per year; the evolution of exacerbation rates was analysed using a Poisson regression model. A trend analysis was performed on the FEV~1~, FVC, FEV~1~/FVC ratio data, Asthma Control Test (ACT) scores and blood eosinophil counts across the inclusion and follow-up periods using a mixed linear model with repeated measurements. A Kaplan--Meier method was used to estimate the duration of treatment with mepolizumab. Statistical analysis was conducted using SAS software (version 9.4 SAS institute Inc., Cary, NC, USA).

Results {#s3}
=======

Patient population {#s3a}
------------------

Of the 160 patients included in the nATU, 146 (91.9%) from 20 participating centres receiving ≥1 injection of mepolizumab were included in this study; 13 (8.1%) patients did not receive mepolizumab and were excluded (supplementary figure S1). One patient received mepolizumab to treat severe chronic obstructive pulmonary disease, while awaiting a lung transplantation, and was considered ineligible by the Scientific Committee and excluded from all analyses except the safety analyses. Overall, 61 patients (41.8%) had 103 injections with a delay \>4 weeks. The reasons for these delays were only documented for 19 injections and included departure for holidays, death of a relative, health problem unrelated to mepolizumab and that the patient forgot.

Baseline demographics and clinical characteristics are outlined in [table 1](#TB1){ref-type="table"}. Of the 62 patients with confirmed allergies, 54 (87.1%) were sensitised to aeroallergens (pollen, dander, mould, cockroaches), 12 (19.4%) had food allergies and five (8.1%) had skin allergies. Almost all patients (93.8%) had ≥1 comorbidity; the most common were ear, nose and throat pathologies (56.2%), cardiovascular diseases (35.0%) and gastro-oesophageal reflux disease (38.7%) ([table 1](#TB1){ref-type="table"}). In addition, 38.7% of patients had nasal polyps, 17.5% had allergic rhinitis and 16.1% had aspirin-exacerbated respiratory disease. Furthermore, most patients (92.8%) were receiving OCS at inclusion (mean daily dose 20.6±16.5 mg prednisolone equivalent), and 65.9% had previously received omalizumab ([table 1](#TB1){ref-type="table"}).

###### 

Baseline demographics and clinical characteristics

                                                           **Total N=146**
  ------------------------------------------------------- -----------------
  **Age years**                                               58.2±13.6
  **Sex**                                                 
   Female                                                     66 (45.2)
  **BMI kg·m^−2^ (N=137)**                                    27.2±5.1
   Patients with BMI ≥30                                      32 (21.9)
  **Duration of severe asthma years (N=128)**                 13.4±12.1
  **Respiratory allergies**                                   54 (37.0)
  **Disability due to asthma^\#^ (N=127)**                    29 (22.8)
  **Smoking (N=145)**                                     
   Current                                                    11 (7.6)
   Never smoked                                               77 (53.1)
  **Blood eosinophil count cells·µL^−1^ (N=130)**            721.7±500.0
  **Blood IgE total level kIU·L^−1^ (N=78)**                 563.4±773.0
  **Blood neutrophil count ×10^9^ cells·L^−1^ (N=120)**        6.4±3.5
  **ACT score (N=62)**                                        10.2±4.5
  **FEV~1~ mL (N=142)**                                     1883.0±823.2
  **FEV~1~ % predicted value (N=142)**                        62.0±19.4
  **FEV~1~/FVC ratio (N=58)**                                 58.8±12.5
  **Comorbidities**                                       
   Any comorbidity                                           137 (93.8)
   AERD                                                       22 (16.1)
   Allergic rhinitis                                          24 (17.5)
   Cardiovascular disease                                     48 (35.0)
   Depression/anxiety                                         29 (21.2)
   Diabetes                                                   26 (19.0)
   Dyslipidaemia                                              17 (12.4)
   GORD                                                       53 (38.7)
   Nasal polyps                                               53 (38.7)
   Osteoporosis                                               51 (37.2)
   Other comorbidities                                        46 (33.6)
   Sleep apnoea syndrome                                      31 (22.6)
   Smoking/smoking-related comorbidities                       8 (5.8)
  **Prior omalizumab treatment**                              91 (65.9)
  **Current treatment**                                   
   OCS                                                       128 (92.8)
   Methylprednisolone                                          2 (1.6)
   Prednisolone                                               11 (8.9)
   Prednisone                                                111 (89.5)
   Other anti-asthmatic treatment                            136 (93.2)

Data are presented as mean±[sd]{.smallcaps} or n (%). Data were available for all patients unless otherwise stated. Blood eosinophil count was the highest value in the previous 12 months. BMI: body mass index; IgE: immunoglobulin E; ACT: Asthma Control Test; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; AERD: aspirin-exacerbated respiratory disease; GORD: gastro-oesophageal reflux disease; OCS: oral corticosteroid. ^\#^: Declarative item.

In the 12 months preceding mepolizumab initiation, the mean rate of exacerbations was 5.8 events per patient per year, 0.6 and 0.5 of which required hospitalisation and emergency department visits, respectively ([table 2](#TB2){ref-type="table"}). The mean blood eosinophil count at baseline was 722 cells·µL^−1^ and a large proportion (n=115, 86.5%) of patients reported their asthma as having a significant impact on their daily activities.

###### 

Summary of exacerbations during the baseline and follow-up periods

                                                                                          **Baseline (N=134)**    **12 months (N=96)**   **24 months (N=75)**
  --------------------------------------------------------------------------------------- ---------------------- ---------------------- ----------------------
  **Patients with no exacerbations**                                                                                   48 (50.0)              34 (45.3)
  **Exacerbations events per patient per year**                                           5.8±4.4                       0.8±1.1                0.8±0.9
  **Exacerbations requiring hospitalisation events per patient per year**                 0.6±1.5                       0.1±0.4                0.1±0.4
  **Exacerbations requiring an emergency department visit events per patient per year**   0.5±0.9                       0.1±0.3                0.1±0.3

Data are presented as n (%) or mean±[sd]{.smallcaps}. At baseline, 12 patients had missing data. At months 12 and 24 of follow-up, 42 and 31 patients had discontinued treatment, and eight and 40 had no follow-up, respectively.

Follow-up data {#s3b}
--------------

Patients attended on average 8.4 follow-up visits after treatment initiation; the mean follow-up duration was 24.2 months owing to some patients infrequently returning to hospital and having a final visit date that exceeded 24 months. Consecutive injections of mepolizumab were administered, on average, 4.2 weeks apart. A total of 48 patients discontinued mepolizumab during follow-up with the majority reporting a lack of efficacy or lack of efficacy associated with an adverse event (n=29) ([supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02345-2019.figures-only#fig-data-supplementary-materials)). 3 months after their first injection, 91% of patients were still receiving mepolizumab; this reduced to 81% by 6 months and subsequently to 69% and 66% at months 12 and 24.

Mean exacerbation rates for total exacerbations and for those requiring hospitalisation and emergency department visits were lower on-treatment than at baseline ([table 2](#TB2){ref-type="table"}); this trend was observed regardless of blood eosinophil counts at inclusion ([supplementary table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02345-2019.figures-only#fig-data-supplementary-materials)). Compared with baseline, fewer patients used maintenance OCS during follow-up (92.8% at baseline *versus* 41.1% and 34.7% at 12 and 24 months) and those still using OCS required lower doses ([figure 1](#F1){ref-type="fig"}); similar trends were seen when data were stratified by blood eosinophil counts at inclusion (supplementary figure S3 and supplementary table S3). Mean % predicted pre-bronchodilator FEV~1~ improved *versus* baseline at all follow-up time points; mean FEV~1~ steadily increased to approximately 70% of the predicted value during the first 10 months of treatment and then stabilised ([figure 2a](#F2){ref-type="fig"}). Mean FEV~1~/FVC ratios also increased during the first 10 months of treatment and then stabilised. After 3 months of mepolizumab the mean ACT score was 17.4 points; this surpassed the minimal clinically important difference (MCID) of ≥3 points from baseline (10.2 points) and the response was sustained throughout the study period ([figure 2b](#F2){ref-type="fig"} and c). Mean±[sd]{.smallcaps} baseline blood eosinophil counts (cells·µL^−1^) decreased from 722±500.0 to 101±83.9 at 3 months, 75±63.7 at 12 months, and 92±72.3 at 24 months ([figure 3](#F3){ref-type="fig"}).

![a) Change in mean oral corticosteroid (OCS) dose and b) proportion of patients not receiving maintenance OCS during follow-up period. ^\#^: mg prednisolone equivalent. At baseline, eight patients had missing data. At months 12 and 24 of follow-up, 42 and 31 patients had discontinued treatment, and eight and 40 had no follow-up, respectively.](ERJ-02345-2019.01){#F1}

![a) Evolution of percent-predicted pre-bronchodilator forced expiratory volume in 1 s (FEV~1~) b) FEV~1~/ forced vital capacity (FVC) ratio and c) Asthma Control Test (ACT) score during the follow-up period. Continuous lines represent evolution of each score; dotted lines indicate the confidence interval.](ERJ-02345-2019.02){#F2}

![Evolution of eosinophil counts during the follow-up period. Continuous lines represent evolution of each score; dotted lines indicate the confidence interval.](ERJ-02345-2019.03){#F3}

Safety {#s3c}
------

During the study, 276 pharmacovigilance events were reported by 100 patients. Of these, 103 corresponded to drug misuse (all reporting an incorrect dosing interval); 173 were identified as adverse events possibly related to mepolizumab according to patients\' medical records. A total of 99 patients reported 159 non-serious adverse events; 41 patients discontinued mepolizumab as a result of these events (29 reported "drug considered ineffective"). The most commonly reported adverse events which were possibly drug-related (n ≥5% of events) included: drug considered ineffective (n=31); headache (n=14); asthenia (n=12); and asthma (n=10) ([table 3](#TB3){ref-type="table"}). Adverse events of interest included five events in the system organ class (SOC) category "infections and infestations", five events in "vascular disorders", two events related to "allergic and non-allergic reactions" and one event in "local injection site reactions" ([table 4](#TB4){ref-type="table"}). A total of eight patients reported 14 SAEs that were possibly drug related; the most common was asthma (n=3 events). In this study, no patients experienced severe systemic reactions, severe cardiac adverse events or neoplasms. One death was reported (resulting from an asthma exacerbation) and deemed unrelated to mepolizumab by the physician. TABLE 3Adverse events and serious adverse events considered possibly related to study drug, according to patient medical records**Event SOC/PTEventsPatients nTotal173100Adverse events possibly related to mepolizumab n15999** General disorders and administration site conditions62 (39.0)46 Nervous system disorders24 (15.1)20 Respiratory, thoracic and mediastinal disorders21 (13.2)13 Gastrointestinal disorders14 (8.8)10 Musculoskeletal and connective tissue disorders10 (6.3)7 Skin and subcutaneous tissue disorders9 (5.7)9 Vascular disorders5 (3.1)4 Infections and infestations3 (1.9)2 Injury, poisoning and procedural complications^\#^2 (1.3)2 Renal and urinary disorders2 (1.3)2 Cardiac disorders1 (0.6)1 Ear and labyrinth disorders1 (0.6)1 Eye disorders1 (0.6)1 Immune system disorders1 (0.6)1 Investigations1 (0.6)1 Pregnancy, puerperium and perinatal conditions1 (0.6)1 Reproductive system and breast disorders1 (0.6)1**Serious adverse events possibly related to mepolizumab n148** Respiratory, thoracic and mediastinal disorders4 (28.6)2 Musculoskeletal and connective tissue disorders3 (21.4)1 General disorders and administration site conditions2 (14.3)2 Nervous system disorders2 (14.3)2 Infections and infestations2 (14.3)2 Hepatobiliary disorders1 (7.1)1**Most common drug-related adverse and serious adverse events possibly related to mepolizumab (n≥5%)** Drug ineffective31 (17.9^+^)30 Headache14 (8.1^+^)14 Asthma^¶^13 (7.5^+^)3 Asthenia12 (6.9^+^)12Data are presented as n or n (%), unless otherwise stated. SOC: System Organ Class; PT: preferred term. ^\#^: Excluding 103 events of inappropriate schedule of product administration for 61 patients; ^¶^: included exercise induced asthma, asthmatic crisis, and aggravated condition; ^+^: percentage of total drug-related adverse events and serious adverse events (N=173). TABLE 4Adverse events of interest (N=15)**Event SOC/PTEventsAdverse events related to allergic and non-allergic reactions**2 (13.3) Generalised rash1 (6.7) Rash1 (6.7)**Local injection-site reactions**1 (6.7) Injection-site erythema1 (6.7)**Infections^\#^**5 (33.3) Herpes virus infection1 (6.7) Oral herpes1 (6.7) Pharyngitis1 (6.7) Pneumonia^¶^1 (6.7) Purulent sputum^¶^1 (6.7)**Malignancies^+^**^§^**Vascular disorders**5 (33.3) Hot flush3 (20.0) Capillary fragility1 (6.7) Hypertension1 (6.7)**Cardiac disorders** Palpitations1 (6.7)Data are presented as n (%). SOC: System Organ Class; PT: preferred term. ^\#^: Based on the Infections and Infestations SOC; ^¶^: events deemed serious by the treating investigator; ^+^: based on the Neoplasms SOC; ^§^: not reported.

Discussion {#s4}
==========

Early access programmes (*e.g.* the nATU) allow patients who do not meet the strict eligibility criteria for RCTs, but might still benefit from mepolizumab treatment, to gain access to the drug before its commercialisation. Moreover, data collected from these programmes can provide insights on the wider use of mepolizumab in a patient population that closely resembles real life \[[@C19]\]. Here, we investigated the effectiveness and safety of mepolizumab using data from patients with severe eosinophilic asthma enrolled in the nATU. We found that mepolizumab was associated with several clinical benefits, including clinically meaningful reductions in exacerbations and daily OCS doses, consistent with results from two RCTs that assessed these outcomes separately \[[@C14]\].

We identified several indicators of severe disease among patients in the nATU, which included high annual exacerbation rates, with most patients requiring maintenance OCS and experiencing a considerable disease burden. The degree of disease severity among these patients was generally greater than that of those enrolled in RCTs. For instance, patients enrolled in the Phase III MENSA and MUSCA studies had a mean rate of 2.7--3.8 exacerbations per year before screening (*versus* 5.8 in this study) \[[@C13], [@C15]\]. Additionally, the proportion of patients in this study requiring maintenance OCS at inclusion was higher (92.8%) than in the MENSA and MUSCA studies (23--27%) \[[@C13], [@C15]\]. These findings are not unexpected, since patients in the nATU had a justified need to receive mepolizumab before it became commercially available. There also appears to be an over-representation of late-onset, eosinophilic asthma with nasal polyposis in the nATU population compared with the MUSCA trial (38.7% of patients in the nATU *versus* 17--21% in MUSCA) \[[@C15]\]. Nonetheless, disease severity in this study was similar to that of a real-world study of patients receiving omalizumab \[[@C20]\] and other early access programmes, including the omalizumab and dupilumab ATUs in France \[[@C21], [@C22]\].

The prevention of exacerbations remains an important therapeutic target for patients with asthma \[[@C23]\]. In this study, we observed an 86.2% reduction from baseline in exacerbation rate after both 12 and 24 months of follow-up. In MENSA (MEpolizumab as adjunctive therapy iN patients with Severe Asthma) and MUSCA (Mepolizumab adjUnctive therapy in subjects with Severe eosinophiliC Asthma), exacerbation rates were reduced by 53% and 58% following 32 and 24 weeks with mepolizumab (100 mg SC) *versus* placebo \[[@C14], [@C15]\]. Other studies based on real-world data have also associated mepolizumab with a reduction in exacerbations \[[@C24]--[@C27]\]; in one recent example (n=25), 82.6% of patients experienced fewer exacerbations and 47.8% experienced no exacerbations on-treatment \[[@C24]\]. When we analysed data by blood eosinophil count at inclusion, reductions in exacerbation rate and OCS use/dose were seen across all subgroups (although the sample sizes were small). Interestingly, the rates of exacerbations requiring hospitalisation were low considering the severity of disease among the study population. This may be owing to the majority of patients being recruited in University hospitals specialising in severe asthma, where patients typically have action plans to facilitate disease management.

We found that approximately 33.0% and 62.5% of patients receiving mepolizumab experienced ≥50% reductions in daily OCS dose at 6 and 12 months (supplementary section 2). M[ontero-]{.smallcaps}P[erez]{.smallcaps} *et al.* \[[@C24]\] also reported that approximately 60% of patients experienced a reduction in OCS dose after 12 months of treatment (although this was not limited to reductions ≥50%). It should be noted that in the SIRIUS (SteroId ReductIon with mepolizUmab Study) RCT, ≥50% reductions in daily OCS dose from baseline were observed among 54% of patients following 6 months of mepolizumab treatment \[[@C14]\]. Although this is a greater proportion of patients than in our study, OCS doses are typically lowered more gradually in a real-world setting than in the down-titration protocols followed in RCTs. It is therefore likely that OCS tapering was conducted more slowly in our study than in SIRIUS, as supported by peak improvements in FEV~1~ and ACT score after 6 months of mepolizumab in the nATU. Moreover, we observed a relapse in OCS use/dose at 24 months of follow-up. However, this may be explained by differences in the number of patients between timepoints (18 months; n=91 and 24 months; n=75).

With regards to safety, we found that over the 24-month study period, headache and asthma were the most commonly reported adverse events and the occurrence of allergic, non-allergic and injection-site reactions was low. These results are in agreement with those from RCTs \[[@C14], [@C15]\], and indicate that mepolizumab is well tolerated in a setting that more closely resembles real life. During the nATU, 48 patients discontinued mepolizumab, 11 of whom reported a lack of drug efficacy associated with adverse events. The high discontinuation rate observed (32.9%) may be explained by mepolizumab being a new product at the time of the study with no market approval, and thus no available stopping rules or guidelines. As such, physicians could stop treatment after a few months if no benefit was seen.

The main limitation of this study was the retrospective nature of the data collection and analysis. It should be noted that ACT score data were missing for approximately 40--60% of patients, although we did observe changes from baseline in ACT scores that exceeded the MCID in those patients with data available. The patients who discontinued mepolizumab in this study (owing to adverse events or lack of efficacy) were not included in the safety and efficacy results; since these measures depend on both the number of patients participating in the analysis and the duration of treatment, the data reported should be interpreted with caution. In addition, baseline ICS doses were not recorded in the medical data used for this study; these therefore could not be included in our assessments of baseline characteristics and evolution of disease among the nATU patient population. Results may also be subject to confounding factors, such as more stringent compliance, resulting from the regular contact with healthcare professionals that is required for biologic administration, or from patients having previously received another biologic therapy (*e.g.* omalizumab). Finally, patients in this study had particularly severe disease, based on the nATU criteria for early access to treatment, and were treated at University hospitals with expertise in managing severe asthma. As a result, our data may not be reflective of the overall severe asthma population, particularly those who receive care outside of this environment.

Nonetheless, these data from patients with severe eosinophilic asthma who received mepolizumab in the French early access programme confirm the effectiveness of mepolizumab in reducing exacerbation rates and OCS dependency as well as improving lung function in a setting which closely resembles real-life use. In addition, safety findings were consistent with those observed in clinical trials. Although additional studies are needed to fully assess the safety and effectiveness of mepolizumab in real-world, long-term, clinical practice, this analysis provides useful information for physicians who are considering treatment options for their patients with severe eosinophilic asthma.
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